ProfileGDS5678 / 1424642_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 90% 90% 91% 90% 90% 91% 90% 91% 90% 89% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2180290
GSM967853U87-EV human glioblastoma xenograft - Control 27.3428590
GSM967854U87-EV human glioblastoma xenograft - Control 37.2622590
GSM967855U87-EV human glioblastoma xenograft - Control 47.297590
GSM967856U87-EV human glioblastoma xenograft - Control 57.1999690
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1758491
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9751790
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2565590
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.3312791
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1592590
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2818791
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.191590
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0660989
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4571391